Oncology Institute, Inc. (DFPH) intrinsic value & 10-year financials
Oncology Institute, Inc. (DFPH) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue grew 21.8% a year to $502.7M, with an average return on invested capital of -310.0%.
- Graham intrinsic value
- —
- Revenue (FY2025)
- $502.7M
- Revenue growth (7-yr CAGR)
- 21.8%
- ROIC (10-yr avg)
- -310.0%
- Free cash flow (FY2025)
- -$27.8M
DFPH 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $502.7M | -$60.6M | -$0.54 | -$27.8M | -7.2% | -53.4% |
| FY2024 | $393.4M | -$64.7M | -$0.71 | -$30.3M | -15.3% | -55.1% |
| FY2023 | $324.2M | -$83.1M | -$0.92 | -$40.9M | -23.8% | -44.1% |
| FY2022 | $252.5M | $152.0K | -$0.21 | -$67.3M | -32.5% | -40.7% |
| FY2021 | $203.0M | -$10.9M | -$0.16 | -$35.5M | -22.6% | -1662.7% |
| FY2020 | $187.5M | -$441.2K | -$0.24 | -$1.8M | -0.4% | -4.3% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Oncology Institute, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Oncology Institute, Inc. has historically struggled to out-earn its cost of capital, averaging just -35.7% ROIC.
Oncology Institute, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Oncology Institute, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-17.94 per share.